SG Americas Securities
VERV

SG Americas Securities’s Verve Therapeutics VERV Stock Holding History

SG Americas Securities’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,064
Closed -$137K – 3637
2025
Q1 		$137K Buy
+30,064
New +$201K ﹤0.01% 2818
2024
Q4 		– Sell
-29,954
Closed -$145K – 3653
2024
Q3 		$145K Buy
+29,954
New +$174K ﹤0.01% 2769
2024
Q1 		– Sell
-50,802
Closed -$708K – 3464
2023
Q4 		$708K Buy
50,802
+32,087
+171% +$398K 0.01% 1249
2023
Q3 		$248K Buy
+18,715
New +$301K ﹤0.01% 2182
2023
Q1 		– Sell
-15,346
Closed -$297K – 3578
2022
Q4 		$297K Buy
15,346
+7,524
+96% +$199K ﹤0.01% 1931
2022
Q3 		$269K Buy
+7,822
New +$250K ﹤0.01% 2089
2021
Q4 		– Sell
-7,015
Closed -$330K – 3832
2021
Q3 		$330K Buy
+7,015
New +$413K ﹤0.01% 2855

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SG Americas Securities's VERV Position: Q2 2025 in Review

SG Americas Securities sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 30,064 shares — an estimated $137K sold.

SG Americas Securities first reported a position in VERV in Q3 2021 and held it in 7 quarters. The position peaked at $708K in Q4 2023. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • SG Americas Securities reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 30,064 Verve Therapeutics shares in Q2 2025, an estimated $137K.
  • SG Americas Securities first reported a position in Verve Therapeutics in Q3 2021 and held it in 7 quarters.
  • SG Americas Securities's Verve Therapeutics position peaked at $708K in Q4 2023.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.